In these CML patients, the expression level of CFL1 significantly increased from 1.86 (0.77-3.04) to 2.99 (1.58-4.57) after a 3-month imatinib therapy(p<0.001) (Supplementary Figure 1). Here, CFL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.